Articles related to Urology

Understanding the complexities of neuroendocrine prostate cancer (NEPC) is crucial for advancing diagnosis and treatment. Insights into lineage plasticity and novel diagnostic tools, including PET imaging and liquid biopsies, are paving the way for more effective management strategies.

Recent studies highlight the potential of cabozantinib plus atezolizumab in improving progression-free survival for mCRPC patients and confirm the benefits of high-dose radiotherapy in high-risk prostate cancer treatment, offering new insights into personalized care strategies.

Recent insights challenge the conventional wisdom on testosterone supplementation in age-related hypogonadism, highlighting the critical need for precise diagnosis and evidence-based treatment approaches amidst growing patient inquiries.

In a significant advancement, one physician’s minimally invasive technique for treating membranous urethral strictures post-radiation therapy showcases promising outcomes, including improved urethral patency and reduced operative complications, marking a pivotal shift in patient management strategies.

In the phase 3 GETUG-AFU 18 trial, high-dose radiotherapy (80 Gy) combined with long-term androgen deprivation therapy markedly improved 10-year progression-free and overall survival in high-risk prostate cancer patients, without additional toxicity.

In a rigorously designed trial involving more than 5,000 participants, researchers observed that testosterone treatment in hypogonadal men aged 45-80 was associated with a 1.43 times higher risk of clinical fractures compared to placebo. These findings are crucial in re-evaluating the therapeutic approach to testosterone replacement in this demographic.